Difference between revisions of "Comment Resolutions"
Jump to navigation
Jump to search
(21 intermediate revisions by 2 users not shown) | |||
Line 27: | Line 27: | ||
| [[Media:QIBA CTA Comments all resolved.xlsx| Public Comment Resolutions 2020-03-12]] | | [[Media:QIBA CTA Comments all resolved.xlsx| Public Comment Resolutions 2020-03-12]] | ||
|- | |- | ||
− | | [[Media: | + | | [[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf| CT Atherosclerosis 2023-03-28]] |
| Clinically Feasible | | Clinically Feasible | ||
− | | 2023. | + | | 2023.03.07 |
− | | [[Media: | + | | [[Media:CTA Profile Clinically Feasible Comment Resolutions.2023Mar28.pdf|Clinically Feasible Comment Resolutions 2023-03-28]] |
|- | |- | ||
| [[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density 2020-09-04]] | | [[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density 2020-09-04]] | ||
| Public Comment | | Public Comment | ||
| 2019.10.16 | | 2019.10.16 | ||
− | | [[Media:QIBA Lung Density Comments resolved.xlsx| Public Comment Resolutions 2020-09-04]] | + | |[[Media:QIBA Lung Density Comments resolved.xlsx| Public Comment Resolutions 2020-09-04]] |
|- | |- | ||
− | | [[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2018.11.18-clean-3.pdf|CT Small Lung Nodule Screening 2018-11-18]] | + | |[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2018.11.18-clean-3.pdf|CT Small Lung Nodule Screening 2018-11-18]] |
| Technical Confirmation | | Technical Confirmation | ||
| 2020.04 | | 2020.04 | ||
− | | | + | |[[Media:CT Small Lung Nodule Profile Clinically Feasible Comment Resolutions.2023Aug18.pdf|Clinically Feasible Comment Resolutions 2023-08-18]] |
|- | |- | ||
| colspan="4" align="center" style="background:#dddddd" | '''MR Profiles''' | | colspan="4" align="center" style="background:#dddddd" | '''MR Profiles''' | ||
Line 69: | Line 69: | ||
| [[Media:QIBA MSK BC Public Comment Resolutions.pdf| Public Comment Resolutions]] | | [[Media:QIBA MSK BC Public Comment Resolutions.pdf| Public Comment Resolutions]] | ||
|- | |- | ||
− | | [[Media:QIBA DCE- | + | | [[Media:QIBA DCE-Profile - v2.0 - Consensus Document.pdf|MR DCE-MRI Quantification (DCEMRI-Q) 2023-12-06]] |
− | | | + | | Consensus |
− | | | + | | 2023.12-06 |
− | | | + | | [[Media:QIBA DCE-MRI Public Comment Resolutions.pdf| Public Comment Resolutions]] |
|- | |- | ||
| [[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf| MR Elastography of the Liver 2022-02-14]] | | [[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf| MR Elastography of the Liver 2022-02-14]] | ||
Line 78: | Line 78: | ||
| 2021.12.16 | | 2021.12.16 | ||
| [[Media:QIBATechnicalConfirmationResolutions MRE.pdf| Technical Confirmation Resolutions 2022-02-14]] | | [[Media:QIBATechnicalConfirmationResolutions MRE.pdf| Technical Confirmation Resolutions 2022-02-14]] | ||
− | |||
|- | |- | ||
− | | [[Media: | + | | [[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC) 2022-12-15]] |
− | |Clinically Feasible | + | | Clinically Feasible |
− | |2022.12.15 | + | | 2022.12.15 |
− | |Clinically Feasible 2022-12-15 | + | | [[Media:QIBA DWI-MR Clinical Feasibility Resolutions.pdf| Clinically Feasible Resolutions 2022-12-15]] |
− | | | + | |- |
+ | | [[Media:QIBA PDFF Profile Stage2 FINAL.pdf| MR MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]] | ||
+ | |Consensus | ||
+ | |2023.09.08 | ||
+ | | [[Media:QIBA PDFF Public Comment Resolutions.pdf| Public Comment Resolutions 2023-11-14]] | ||
|- | |- | ||
| colspan="4" align="center" style="background:#dddddd" | '''PET/NM Profiles''' | | colspan="4" align="center" style="background:#dddddd" | '''PET/NM Profiles''' | ||
Line 119: | Line 122: | ||
| 2019.12.18 | | 2019.12.18 | ||
| [[Media:QIBA US SWS Comments 2021-02-06-final.xlsx| Public Comment Resolutions 2021-02-06]] | | [[Media:QIBA US SWS Comments 2021-02-06-final.xlsx| Public Comment Resolutions 2021-02-06]] | ||
+ | |- | ||
+ | | [[Media:QIBA US SWS Profile 2023-02-07.pdf|US Shear Wave Speed for Liver Fibrosis 2023-02-07]] | ||
+ | | Clinically Feasible | ||
+ | | 2023.02.07 | ||
+ | | [[Media:QIBA US SWS Comments 2023-02-20-v2.xlsx| Clinically Feasible Comment Resolutions 2023-02-20]] | ||
+ | |- | ||
+ | | [[Media:QIBA US SWS Profile 2023-02-07.pdf|US Shear Wave Speed for Liver Fibrosis 2023-02-07, marked-up version]] | ||
+ | | Clinically Feasible | ||
+ | | 2023.12.13 | ||
+ | | [[Media:2023 12 13 SWS BC QIBA Technical Confirmation Resolutions.xlsx| Clinically Feasible Comment Resolutions 2023-12-13]] | ||
+ | |- | ||
+ | | [[Media:SWS Profile Final Candidate February 07 2023 CLEAN.pdf|US Shear Wave Speed for Liver Fibrosis 2023-02-07, clean version]] | ||
+ | | Clinically Feasible | ||
+ | | 2023.12.13 | ||
+ | | [[Media:2023 12 13 SWS BC QIBA Technical Confirmation Resolutions.xlsx| Clinically Feasible Comment Resolutions 2023-12-13]] | ||
+ | |- | ||
+ | | [[Media:QIBA US VBF Profile 2023-12-13-tracked-changes.pdf|US Volume Blood Flow (VBF) Profile 2023-12-13 (tracked changes)]] | ||
+ | | Consensus | ||
+ | | 2023.12.13 | ||
+ | | [[Media:2023 12 13 VBF BC QIBA Consensus Confirmation Resolutions.xlsx| Consensus Comment Resolutions 2023-12-13]] | ||
|- | |- | ||
|} | |} |
Latest revision as of 14:53, 21 December 2023
Comments received during Public Comment, Clinically Feasible (formerly Technical) Confirmation, or during a Profile ballot, are reviewed by the originating Biomarker Committee.
Per the QIBA Process, committees record how each collected comment was resolved and those resolutions are posted here.